Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
about
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsPlatelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery diseaseClopidogrel: the data, the experience, and the controversies.Properties of soluble glycoprotein VI, a potential platelet activation biomarker.Genetic polymorphisms of platelet receptors in patients with acute myocardial infarction and resistance to antiplatelet therapy.Variability of platelet aggregation in patients with clopidogrel treatment and hip fracture: A retrospective case-control study on 112 patientsP2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease.High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice.Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome.Monitoring oral antiplatelet therapy: is it justified?Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management.Functional testing methods for the antiplatelet effects of aspirin.Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?A contemporary viewpoint on 'aspirin resistance'.Genetic and non-genetic factors affecting the response to clopidogrel therapy.Monitoring aspirin and clopidogrel response: testing controversies and recommendations.Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures.Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects.Global Trends in Aspirin Resistance-Related Research from 1990 to 2015: A Bibliometric Analysis.Suspected aspirin resistance in individual healthy adult warmblood horses.Antiplatelet agents in hemodialysis.Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping.Aspirin response: Differences in serum thromboxane B2 levels between clinical studies.Aspirin can stimulate luminol-enhanced chemiluminescence of activated platelets.Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals.Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study.β-blockers are associated with decreased leucocyte-platelet aggregate formation and lower residual platelet reactivity to adenosine diphosphate after angioplasty and stenting.Aspirin's effect on platelet inhibition in migraineurs.Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin
P2860
Q26775125-70690A25-3AE6-4E8B-A5B4-9A30A44ED46FQ27027247-57D2B666-530A-40AA-A0FC-CB3FBD178EDAQ30573045-0DA9C36F-A090-4936-8351-4B00BF22DFC1Q33419547-4F620B17-80B3-413A-81E8-7F74869EE5C7Q34113879-6FE038CF-C842-40E7-8AEA-AFD7981DE8EEQ35691358-147FE911-C862-4844-8081-04500632AFBFQ36164883-C4123FE0-A63F-4DE6-981E-6D41C851656CQ36366209-4BD26F04-650D-4881-853F-BE89948A5CEAQ37056745-6F4578FD-7B4D-4B24-A76F-C959FF7528D8Q37207281-92E6729B-0CE9-4EF0-8164-090BEFEAE2C2Q37311337-81528A91-4B71-4F25-8C0E-88EB1BE97102Q37362783-C0C5B524-EA87-4E86-A558-AD974D3B08CFQ37588694-A8AB607F-C17D-427D-A003-35C49B665E50Q37809122-65DEEBCA-6366-4004-AAC6-5DA98000A023Q37841562-FAAA81C6-C1FB-4094-9748-FCF132915239Q37882712-7834505A-47FD-46A2-9981-0C8DEF26DD1EQ37973457-290B09E5-5B68-4C2E-B7B5-71399B2F472AQ37989558-78A7B04A-F959-42AC-8819-7FE75B19C31BQ37991382-2696F9CF-0113-4A6E-AEB5-9CEE2EB8D8D9Q38099235-4207D2B3-D5EE-4EF9-8093-53CF23F0D69BQ38243854-4A0B7A0C-0724-4DD8-9CC7-DFD415875E30Q38543311-F3B213F4-BC61-459D-B893-A7EF045A85BBQ38664158-349854EA-644D-4BBA-830A-3F73568FA51EQ38846890-02F84646-D823-4622-BB65-DB107466E16DQ39032565-18C0DF72-88AD-4A38-959B-E75E02903733Q39908656-278D02D6-2D56-4823-94D1-5DCD8825D261Q40498149-64D51C1B-5DBE-4BB6-912E-CA1DA31248FFQ41485945-FDDC3A03-1686-4983-AD39-B695F0902F75Q43072125-A20F6650-2473-4A19-8BC4-8B226EC93EFCQ45180360-5C1FA57F-2853-4A4F-B7A2-3F1EC857F1DDQ46638114-0B00518A-6BAA-4949-BF46-14F22277C15CQ51119287-D8F41975-9EE1-4C19-B794-FC7A75955E53Q51347759-6A7AC76B-2B3C-4730-B32F-C46A12C2E3ADQ53072423-5D64F3C5-FB0C-4188-B5C6-B3DCD7E3AC37Q53298721-A2762DF4-C4BA-4732-8C97-CC7DD97CACF7Q53837582-60D8F81F-EF0A-4416-9F90-BA06091C69C3Q58411822-48639FF9-4F58-4192-950B-FE2B49A68C36
P2860
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
@ast
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
@en
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
@nl
type
label
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
@ast
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
@en
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
@nl
prefLabel
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
@ast
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
@en
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
@nl
P1476
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
@en
P2093
M Cattaneo
P304
P356
10.1111/J.1538-7836.2007.02498.X
P407
P478
P577
2007-07-01T00:00:00Z